Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610880 | 0.81 | MEN1 (0.46) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL10155680 | 0.80 | KDM1A (0.47) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL31546674 | 0.77 | L3MBTL1 (0.58) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL10155681 | 0.76 | LMNA (0.44) | MEN1KMT2AMAPTPOLBALDH1A1 | |
| SCHEMBL11068063 | 0.73 | KMT2A (0.74) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL6678010 | 0.73 | RAB9A (0.50) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL6677984 | 0.72 | RAB9A (0.49) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL7245271 | 0.70 | MAPT (0.50) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL6676866 | 0.70 | AKR1C1 (0.57) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL6674979 | 0.69 | AKR1C1 (0.56) | MEN1KMT2AMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | MEN1 3671/4885KMT2A 1656/4885MAPT 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.